BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• 

  CRISPR Cas-9 System Doubles Life Expectancy in Mice with Aggressive Cancers

  Scientists in Israel have used the CRISPR Cas-9 gene editing system to destroy cancerous cells in mice without damaging other cells.

  November 23, 2020

   · 

  3 min read

   · 

  Krystle Vermes
• 

  Deals

  Merck Bolsters COVID-19 Pipeline with OncoImmune Acquisition

  Merck acquired OncoImmune and its COVID-19 therapeutic candidate CD24Fc for $425 million in upfront cash two months after the Phase III asset demonstrated efficacy during an interim analysis.

  November 23, 2020

   · 

  3 min read

   · 

  Alex Keown
• 

  Drug Development

  SARS-CoV-2 Causes Heart Damage in 20% of People with Mild or No COVID-19 Symptoms

  COVID-19 is a cardiac condition as much as it is a pulmonary or respiratory disease. This knowledge is so recent that it often is overlooked by non-cardiologists, according to physicians speaking at Demy-Colton Virtual Salon, “COVID-19: Surprising Cardiac Findings & Concern about the Potential Impact.”

  November 23, 2020

   · 

  4 min read

   · 

  Gail Dutton
• 

  FDA

  Regeneron’s COVID-19 Antibody Cocktail Now Available for Some Patients Under EUA

  Late Friday, the FDA gave the green light to Regeneron’s REGN-COV2, a combination of casirivimab and imdevimab.

  November 23, 2020

   · 

  3 min read

   · 

  Alex Keown
• 

  Drug Development

  Immunocore’s Tebentafusp Successfully Activates T Cells Against Uveal Melanoma

  Uveal melanoma is a rare and aggressive form of melanoma. It primarily affects the eye. There are no currently accepted optimal management regimens or treatments.

  November 23, 2020

   · 

  2 min read

   · 

  Mark Terry
• 

  BioCapital

  Novavax’s COVID-19 Vaccine Shows Efficacy in Monkeys, but Does That Translate to Humans?

  Maryland-based vaccine company Novavax said its COVID-19 vaccine candidate, NVX‑CoV2373, prevented SARS-CoV-2 infection in monkeys, hinting that the product could likewise prove effective in humans.

  November 23, 2020

   · 

  2 min read

   · 

  Brandon May
• 

  Drug Development

  AstraZeneca’s COVID-19 Vaccine Boasts Strong Results with Up to 90% Efficacy

  AstraZeneca and the University of Oxford announced results from an interim analysis of their COVID-19 vaccine, AZD1222. The analysis was from the trials in the UK and Brazil and demonstrated efficacy of up to 90%.

  November 23, 2020

   · 

  4 min read

   · 

  Mark Terry
• 

  FDA

  Giving the Gift of Time, FDA Approves First Treatment, Zokinvy, for Rare Childhood Aging Diseases

  Eiger’s Zokinvy is the first-ever approved treatment for children with Huchinson-Gilford Progeria Syndrome and processing-deficient Progeroid Laminopathies.

  November 23, 2020

   · 

  2 min read

   · 

  Kate Goodwin
• 

  Sponsored | China’s Establishing Patent Linkage System More Favorable to Generic Drug Companies or Innovator Drug Companies?

  The fourth Amendment of the China Patent Law has been deliberated and was passed on October 17, 2020. It will come into force on June 1, 2021. For the medical industry, China’s proposed patent linkage system can be more favorable to generic drug companies than the U.S. system.

  November 23, 2020

   · 

  2 min read

   · 

  SHAO, Wei and KOU, Fei PhD from China NTD
• 

  Drug Development

  Biopharma Update on the Novel Coronavirus: November 24

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for November 24, 2020.

  November 23, 2020

   · 

  5 min read

   · 

  BioSpace Editorial Staff